PRIME-ROSE has established a dedicated data-sharing team that have regular, monthly meetings. In the most recent meeting that took place om May 27, representatives from all the ongoing DRUP-like clinical trials merged another Stage I cohort. Altogether, 1051 patients have now been included in 355 shared cohorts, and of these cohorts, 27 have so far been filled across the trials. Data analysis of the filled cohorts will now be initiated, and the results will be published.

In the meeting, biomarker alignment across trials was also addressed. In particular, the current practice of using FGFR2 receptor alternations as a biomarker for FGFR inhibitors, was discussed. Harmonisation of interpretation is key for robust data sharing.

The monthly data sharing meetings currently include a population base of 71 million people, covering the 7 countries of the ongoing DRUP-like clinical trials. The population base where patients are recruited to these trials, will continue to increase as more trials open. Currently, more than 150 patients are discussed in molecular tumour boards each week within this network. Thus, these joint efforts clearly accelerate evidence generation for precision cancer medicine treatments. Updates will be shared regularly on the PRIME-ROSE website (prime-rose.eu).

‍

‍